SomnoMed Ltd (ASX:SOM) has announced that it achieved record September sales, which were 23.8% higher compared to the same period last year.
The company says this compensated for the usually soft Northern summer months of July and August (which saw 13% growth year on year). This resulted in unit sale growth rates of 16.9% for the first quarter of the 2016 financial year.
SomnoMed also says total revenues were up 13.4% for the quarter to $10.94 million.
The company says sales of its SomnoDent devices dominated American sales, accounting for 56% of direct sales.
SomnoMed posted a net profit of $67,000 at 30 June 2016.